Catalyst Pharmaceutical Partners (CPRX)

0.8251 -0.00  -0.53%  May 17, 8:00PM
Add to Watchlists Create an Alert

Catalyst Pharmaceutical Partners R&D Expense Quarterly:

0.7447M for Dec. 31, 2012
View Full Chart

Catalyst Pharmaceutical Partners R&D Expense Quarterly Chart

    Catalyst Pharmaceutical Partners Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2012 0.7447M
    Sept. 30, 2012 0.6548M
    June 30, 2012 0.5327M
    March 31, 2012 0.7273M
    Dec. 31, 2011 0.9602M
    Sept. 30, 2011 0.6141M
    June 30, 2011 0.9056M
    March 31, 2011 0.904M
    Dec. 31, 2010 0.5692M
    Sept. 30, 2010 0.5001M
    June 30, 2010 0.7979M
    March 31, 2010 0.4396M
    Dec. 31, 2009 0.5476M
    Sept. 30, 2009 0.851M
       
    June 30, 2009 1.238M
    March 31, 2009 2.461M
    Dec. 31, 2008 3.272M
    Sept. 30, 2008 2.452M
    June 30, 2008 1.902M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    CPRX R&D Expense Quarterly Benchmarks

    Companies
    Lannett Company 3.572M
    Santarus 6.554M
    AVANIR Pharmaceuticals 6.648M

    CPRX R&D Expense Quarterly Rankings

    Overall 83rd percentile
    1326 of 8002
    Sector 38th percentile
    400 of 650 in Healthcare
    Industry 21st percentile
    51 of 65 in Drug Manufacturers - Specialty & Generic

    CPRX R&D Expense Quarterly Range, Past 5 Years

    Minimum 0.4396M Mar 2010
    Maximum 3.272M Dec 2008
    Average 1.109M